Leukotriene Antagonism in Recruitment of CD49d Expressing Neutrophils in Atopic Subjects

• Status: Completed
• Trial end date: 2018-07-16
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to see if the recruitment of a certain cell type (the alpha 4 integrin (CD49d) expressing neutrophil) during a nasal allergen challenge can be inhibited by pretreatment with an FDA approved leukotriene antagonist (montelukast).

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Mitchell Grayson
• Collaborator: National Heart, Lung, and Blood Institute (NHLBI)
• Treatments: Montelukast

Criteria

Inclusion Criteria:

• 21 - 65 years of age, inclusive

• A personal history of allergic rhinitis (hayfever) (by self-report)

• At least one positive skin test to cat, dust mite mix, Timothy grass, Bermuda grass, Bluegrass, or Ragweed

• Ability to provide informed consent

• Willingness to undergo epicutaneous skin testing

• Willingness to undergo nasal lavages and nasal allergen challenges

• Willingness to undergo 2 peripheral blood draws (10 cc each)

Exclusion Criteria:

• Use of systemic antihistamine in the past 5 days

• Use of intranasal corticosteroids or intranasal antihistamines currently or in the past 2 weeks

• Use of Montelukast currently or in the past week

• Hypersensitivity or allergy to Montelukast

• Inability to perform/undergo any study procedures

• Pregnancy (by subject report) or breastfeeding

• Confirmed or suspected immunodeficiency

• Persistent asthma, atopic dermatitis, or any other co-morbid disease except for allergic rhinitis

• Any symptoms of asthma in the past 2 weeks (shortness of breath, wheezing, and/or use of albuterol)

• Fever (temperature over 99F) currently or in the past 2 weeks

• Current or previous use of a biologic or investigational agent in the past 6 months

• Current or past suicidal thoughts/attempts